potassium citrate (Renodyra® )

Status: Medicine does not meet criteria for AWMSG assessment
This medicine was considered by AWMSG Scrutiny Panel on 6 August 2026. It was considered not suitable for assessment by the Licensed One Wales Medicines Assessment Group due to insufficient evidence on which to undertake a health technology assessment.
Medicine details
Medicine name	potassium citrate (Renodyra® )
Formulation	1080 mg modified release tablets
Reference number	10641
Indication	In adults for: The treatment of patients with kidney stones and hypocitraturia, or chronic calcium oxalate stones. The treatment and prevention of recurrent uric acid lithiasis with or without calcium lithiasis and cystine lithiasis.
Company	Penlan Pharmaceuticals Limited
BNF chapter	Obstetrics, gynaecology & urinary tract disorders
Status	Medicine does not meet criteria for AWMSG assessment
Scrutiny Panel meeting date	06/08/2026